Table 1 Summary of In-vivo data from Fig. 5.

From: A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast cancer tumor growth

Cell line

No. of tumor (n)

Dosing Regimen

Average Tumor Volume (mm3) (Endpoint)

Average Tumor Weight (mg)

KPT-9274

Placebo

KPT-9274

Placebo

KPT-9274

Placebo

MDA-MB-231

16

20

150 mg/kg PO bidx4

128 + 21.7

515.1 + 81.6

64.2 + 9.6

300.2 + 55.8

MDA-MB-468

8

7

100 mg/kg PO bidx4

398.7 + 41

1053.8 + 76

—

—

SUM159

10

10

150 mg/kg PO bidx4

187 + 33.7

524.2 + 90.2

160.8 + 19

463.1 + 81.1